ClinicalTrials.gg
Status unknownNCT04234607Updated Jan 22, 2020

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

A Phase 3 interventional study of TQB2450 and Anlotinib in Extensive Small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 26 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
738
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing benmelstobart in Small Cell Lung Carcinoma — 8 open to participants now, 8 under way, 2 of them phase 3. benmelstobart · Small Cell Lung Carcinoma.

Planned enrollment
Largest of 10
738 · median 45
Started
2020
with 1 other
Phase 3
3 of 10
2 open now
Registered
1st of 10
by date
Lead sponsor
3 of 10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 10 studies testing benmelstobart in Small Cell Lung Carcinoma, this one has the largest planned enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 1st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

8 of the 10 studies testing benmelstobart in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing benmelstobart in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer. The primary outcome measures include PFS and OS. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the informed consent, and then centrally randomized 1:1:1 to the experimental arms and the control arm.

03

Conditions studied

  • Extensive Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. confirmed extensive small cell Lung cancer; 2. Has not received systematic treatment for extensive small cell lung cancer; 3. Has received radiotherapy and chemotherapy for limited stage SCLC must have received radical treatment, and has at least 6 months of no treatment interval from the last treatment to the diagnosis of extensive SCLC; 4. Has based on (RECIST) version 1.1; 5. 18 and 75 years old; (ECOG) performance status of 0 or 1, ≥ 12 weeks; 6. Adequate organ system function; 7. Male or female subjects should agree to use an adequate method of starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ; No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization; 8. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

    1. Has prior therapy with anlotinib, anti-programmed cell death (PD)-1, or other immunotherapy against PD-1/PD-L1; 2. Has central nervous system and/or cancerous meningitis; 3. Has diagnosed and/or treated additional within 5 years prior to randomization. Exceptions include cured basal cell carcinoma of skin and carcinoma in situ of cervix; 4. Has multiple factors affecting oral medication, such as inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc; 5. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; 6. Has spinal cord compression which was not cured or relieved through surgery and/or radiotherapy, or diagnosed spinal cord compression after treatment showed no clinical evidence of disease stabilization prior to randomization ≥1 week; 7. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear; 8. Within 2 months prior to initial administration, subjects with evidence or history of bleeding tendency, regardless of severity; A history of hemoptysis (defined as blood bright red or 1/2 teaspoon) or an unhealed wound, ulcer, or fracture in the 2 weeks prior to initial administration; 9. Has adverse events caused by previous therapy except alopecia that did not recover to ≤ grade 1; 10.Has major surgical procedure、 or obvious traumatic injury within 28 days before randomization; 11. Has arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident including , deep vein thrombosis and pulmonary embolism; 12.Has drug abuse history that unable to abstain from or mental disorders; 13. Has any severe and/or uncontrolled disease; 14. Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first administration.; 15. Severe occurs after administration of other monoclonal antibodies; 16. Active diseases requiring systemic treatment occurred within 2 years prior to first administration ; 17. therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration; 18. Has participated in other anticancer drug clinical trials within 4 weeks; 19. According to the judgement of the researchers, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
738 participants (estimated)

Study arms

  • Experimental
    TQB2450+Anlotinib+ etoposide + carboplatin

    Induced stage:TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3)+Carboplatin(AUC 5 mg/mL/min IV on Day 1( maximum dosage: 800 mg)) maintenance stage:TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

    Drug: TQB2450 · Drug: Anlotinib · Drug: Etoposide · Drug: Carboplatin

  • Experimental
    TQB2450(blank)+Anlotinib+ etoposide + carboplatin

    Induced stage:TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3)+ Carboplatin(AUC 5 mg/mL/min IV on Day 1( maximum dosage: 800 mg)) maintenance stage:TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

    Drug: Anlotinib · Drug: Etoposide · Drug: Carboplatin · Drug: TQB2450(blank)

  • Active comparator
    TQB2450(blank)+Anlotinib(blank)+ etoposide + carboplatin

    Induced stage:TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3)+Carboplatin(AUC 5 mg/mL/min IV on Day 1( maximum dosage: 800 mg)) maintenance stage:TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

    Drug: Etoposide · Drug: Carboplatin · Drug: TQB2450(blank) · Drug: Anlotinib(blank)

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • a multi-target receptor tyrosine kinase inhibitor

  • Etoposide is a cell cycle-specific antitumor drug

  • Carboplatin is cell cycle nonspecific antitumor drug

  • DrugTQB2450(blank)

    Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

  • DrugAnlotinib(blank)

    Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 12 months

  2. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 24 months

Secondary outcomes

  1. Overall response rate (ORR)

    Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) .

    Time frame: up to 12 months

  2. Disease control rate (DCR)

    Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).

    Time frame: up to 12 months

  3. Duration of response(DOR)

    For participants who demonstrate CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: up to 12 months

  4. PFS rate of 6 and 12 months progression-free survival

    PFS rate of progression-free survival at 6 and 12 months: the percentage of subjects who did not develop disease progression or die of any cause at 6 and 12 months after randomization.

    Time frame: up to 12 months

  5. OS rate of 12 and 18 months total survival

    Total survival OS rate at 12 and 18 months: the proportion of subjects who died of any cause at 12 and 18 months after randomization.

    Time frame: up to 12 months

  6. Quality of life score

    Time frame: up to 12 months

  7. Incidence and severity of adverse events (AE) and serious adverse events (SAE)

    Security Index

    Time frame: up to 24 months

07

Study locations

26 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
    • Junbin Wang · Contactbbmcwjb@163.com · 0552-3074480
    • Junbin Wang · Principal investigator
  • Anhui chest hospital
    Hefei, Anhui 230001, China
    • Haohui Fang, Bachelor · Contactfanghh88@163.com · 0551-63615328
    • Haohui Fang · Principal investigator
  • AnHui Provincial Hospital
    Hefei, Anhui 230001, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230001, China
    • Kangsheng Gu, Doctor · Contact13805692145@153.com · 0551-62923093
    • Kangsheng Gu · Principal investigator
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230001, China
  • Beijing chest hospital,capital medical university
    Beijing, Beijing 101149, China
    • Baolan Li, doctor · Contact
    • Baolan Li · Principal investigator
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    • Jinhuo Lai · Contactljh2252@hotmail.com · 0591-86218442
    • Jinhuo Lai · Principal investigator
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian 350011, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
    • Yixin Wan · Contact101937415@qq.com · 0931-8942347
    • Yixin Wan · Principal investigator
    • Junnian Shi · Principal investigator
  • Gansu Provincial Cancer Hospital
    Lanzhou, Gansu 730050, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
    • Jianxing He · Contacthejx@vip.163.com · 020-83062807
    • Jianxing He · Principal investigator
  • The Fiest Affiliated Hospital of Guanghzou University of Chinese Medicine
    Guangzhou, Guangdong 510405, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524000, China
    • Hualin Chen · Contact3549509@qq.com · 0759-2387458
    • Hualin Chen · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530000, China
    • Qitao Yu · Contactyqt178@163.com · 0771-12580
    • Qitao Yu · Principal investigator
  • Guizhou Provincial people's Hospital
    Guiyang, Guizhou 550002, China
    • Xianwei Ye · Contactyxw1205@163.com · 0851-8560232
    • Xianwei Ye · Principal investigator
  • The Second Affiliated Hospital of Hainan Medical University
    Haikou, Hainan 570100, China
    • Haifeng Lin · Contact13322060949@163.com · 0898-66809162
    • Haifeng Lin · Principal investigator
  • Shijiazhuang First Hospital
    Shijiazhuang, Hebei 050011, China
    • Yan Zhang · Contact13315978336@163.com · 0311-86907259
    • Yan Zhang · Principal investigator
  • Hebei Chest Hospital
    Shijiazhuang, Hebei 050048, China
    • Min Zhao · Contactz-mxk1067@126.com · 0311-86911008
    • Min Zhao · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
    • Yan Yu · Contactgpyuyan@163.com · 0451-86298303
    • Yan Yu · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Jinzhou Central Hospital
    Jinzhou, Hubei 434020, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
    • Jianhua Chen · Contactcjh_1000@163.com · 0731-89762220
    • Jianhua Chen · Principal investigator
  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222000, China
    • Jiashu Li · Contactljssm1118@sina.com · 025-85605031
    • Jiashu Li · Principal investigator
  • Jilin Cancer Hospital
    Changchun, Jilin 130000, China
    • Ying Cheng, Doctor · Contactjl.cheng@163.com · 0431-85873390
    • Ying Cheng · Principal investigator
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116027, China
    • Yang Zhang · Contactzydl@medmail.com.cn · 0411-84671291
    • Yang Zhang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2020; primary completion for Dec 2022, 35 months later.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 35 months is close to that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 21, 2020
StartEst.
Jan 2020
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04234607
Responsible party
Sponsor
First posted
Jan 21, 2020
Start date
Jan 2020 (estimated)
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jan 22, 2020

Study contacts

Ying Cheng, doctor
Contact
jl.cheng@163.com
0431-85873390

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib

Start the discussion